Hemorrhagic Tumor Necrosis During a Pilot Trial of Tumor Necrosis Factor-a and Anti-GD3 Ganglioside Monoclonal Antibody

Abstract

Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-a (TNF-a) with the monoclonal antibody R 2 4 (MoAb R 2 4 ) against GD3 ganglioside in patients with metastatic melanoma… (More)

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Minasian2002HemorrhagicTN, title={Hemorrhagic Tumor Necrosis During a Pilot Trial of Tumor Necrosis Factor-a and Anti-GD3 Ganglioside Monoclonal Antibody}, author={Lori M. Minasian and Marc A Rosenblum and Thomas Steffens}, year={2002} }